Impact of topical therapy on visual function

Article

Results of the Low-pressure Glaucoma Treatment Study revealed

Fundamentally, glaucoma is a neurodegenerative disease and from experimental models we know that alpha2 agonists are neuroprotective agents. As such, the Low-pressure Glaucoma Treatment Study (LoGTS) was conceived to examine the possibility of other therapeutic measures being useful in the management of glaucoma other than a simple intraocular pressure (IOP)-lowering medication.

An important trial

To ensure we had an appropriate study group we set out certain exclusion parameters, which were untreated IOP > 21 mmHg, VF mean deviation worse than –16 decibels, or contraindications to study medications. To allow for a higher patient attrition in the brimonidine group to an expected ocular allergy, both eyes received twice-daily monotherapy in blocks of 7 (4 brimonidine, 3 timolol) by an independent pharmacy in new white bottles.

We determined the efficacy of the treatments mainly on the VF progression in either of the patient's eyes, but it had to be defined as the same three or more points with a negative slope {≥–1 db/year on three consecutive tests, which was assessed by pointwise linear regression. We also examined the level of our study groups' progression on glaucoma change probability maps (GCPM) of pattern deviation and the 3omitting method for pointwise linear regression as a secondary outcome of the treatment efficacy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.